| 000 | 01651nam a2200361 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223025950.0 | ||
| 008 | 091114s2009 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.19.04.M.Sc.2009.Ah.F | ||
| 100 | 0 | _aAhmed Magdy Rabea | |
| 245 | 1 | 0 |
_aFirst line therapy in multiple myeloma / _cAhmed Magdy Rabea ; Supervised Nasr Mohamed Ali Allahloubi , Ahmed Galal , Fatma Aboelkasem |
| 246 | 1 | 5 | _aالعلاج الاولى للميلوما المتعددة |
| 260 |
_aCairo : _bAhmed Magdy Rabea , _c2009 |
||
| 300 |
_a123P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology (Medical) | ||
| 520 | _aThe aim : to review the recent literature comparing the new therapeutics that has improved the quality of life and prolonged survival , also to highlight the results of bone marrow transplantation as initial treatment . Multiple myeloma (MM) is a malignant disorder characterized by the proliferation of a single clone of plasma celle derived from B cells in the bone marrow causing disruption of normal bon marrow function | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aASCT | |
| 653 | 4 | _aMultiple myeloma | |
| 653 | 4 | _aThalidomide | |
| 700 | 0 |
_aAhmed Galal , _eSupervisor |
|
| 700 | 0 |
_aFatma Aboelkasem , _eSupervisor |
|
| 700 | 0 |
_aNasr Mohamed Ali Allahloubi , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 902 | _a1 | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c24517 _d24517 |
||